A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Panobinostat
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2017.
- 23 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2017.
- 23 May 2017 Status changed from suspended to active, no longer recruiting.